Inclusion Criteria:  Parents of any age are eligible for this study. Index child must be between the ages of 1 and 14.9 years at the time of the parent's enrollment Parents of an index child with a newly diagnosed with de novo ALL are eligible for this study Parent must speak English or Spanish in order to participate in the consent process and provide consent. The parent's language skills must be sufficient to understand the study requirements and complete the survey and interview questions. For parents who cannot read/write or do not feel comfortable reading/writing, the survey can be read aloud by the research nurse, clinical research associate, or other clinical research team member from the treating institution At the parent's entry to the study, the index child must be receiving induction chemotherapy for newly diagnosed ALL at the enrolling institution. The index child may be enrolled in therapeutic clinical ALL trials or receiving ALL therapy per standard of care All parents must sign a written informed consent for their participation in the study All institutional and National Cancer Institute (NCI) requirements for human studies must be met  Exclusion Criteria:  Parents of index children with any of the following clinical characteristics will be excluded from the study:  KMT2A-R (formerly MLL-R) not receiving ALL therapy Mixed-phenotype acute leukemia (MPAL) not receiving ALL therapy Burkitt's leukemia